Impact of haemodiafiltration on the pharmacokinetics of potent antibiotics.
Completed
- Conditions
- End stage kidney diseaseRenal and Urogenital - Kidney disease
- Registration Number
- ACTRN12616000078459
- Lead Sponsor
- niversity of Otago
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Stable haemodialysis patients aged from 18 - 75 years.
able to give informed consent.
Exclusion Criteria
Unable to give consent.
Known penicillin allergy or previous allergy to meropenem or tazocin.
An intercurrent infection requiring antibiotic therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of pharmacokinetics of meropenem or tazocin for stable haemodialysis patients during a single session of haemodiafiltration.<br>The pharmacokinetics of these drugs during a HDF session will be estimated using a population pharmacokinetic approach with the standard software NONMEM (ver 7.2.0).<br>Cmax, Tmax, AUC and clearances will all be measured.[Timed sampling across a dialysis session.<br>Baseline pre-antibiotic dose, then at 15min,prior to commencement of HDF.<br>Following commencement of HDF, blood samples will be collected at 15 min, 30 min, 45 min, 60 min, 2hours, and 4hours (completion of HDF session and a final sample 1 hour post HDF.<br>Blood samples wil be taken before and after dialysis membrane.<br>Dialysate samples: baseline, 30 mins, 60 mins, 2 hours, 4 hours.<br>]
- Secondary Outcome Measures
Name Time Method one[None]